Irbesartan And Hydrochlorothiazide Bristol (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release. When combined with hydrochlorothiazide, which reduces sodium reabsorption in the distal tubule, the pair lowers vascular resistance and plasma volume, resulting in blood‑pressure reduction.

The appropriate dose is determined by the prescribing clinician based on the patient’s blood‑pressure goals, renal function, and concomitant therapies. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety in pregnancy and lactation has not been established. The product should be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and it is generally contraindicated in known pregnancy.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with an ACE‑inhibitor/thiazide combination, the irbesartan/hydrochlorothiazide pair offers similar blood‑pressure control but may have a lower incidence of cough and angioedema because it does not inhibit ACE. Both classes share risks of electrolyte disturbances and renal effects.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister or container, protect from moisture and direct sunlight, and ensure the packaging remains sealed until use.

The medication is taken orally, usually once daily, with or without food. Tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically directed by a healthcare professional.

Serious adverse events include severe hypotension, hyperkalemia, acute renal impairment, and angioedema. Patients should seek immediate medical attention if they experience sudden dizziness, swelling of the face or throat, rapid weight gain, or marked changes in urine output.

The combination is contraindicated in patients with severe renal impairment, hyperkalemia, known hypersensitivity to either component, and in women who are pregnant. Caution is also advised for individuals with hepatic failure or severe electrolyte disturbances.